Seres Therapeutics (MCRB) director Richard Kender awarded 150,000 stock options

Rhea-AI Filing Summary

Kender Richard N reported acquisition or exercise transactions in this Form 4 filing.

Seres Therapeutics, Inc. director and officer Richard N. Kender reported receiving a grant of stock options covering 150,000 shares of common stock. These options give him the right to buy company shares and were reported as a direct beneficial holding.

According to the filing, the option award vests and becomes exercisable in 36 equal monthly installments, providing long-term, incremental equity-based compensation tied to his continued service with the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kender Richard N

(Last) (First) (Middle)

C/O SERES THERAPEUTICS, INC.

101 CAMBRIDGE PARK DRIVE

(Street)

CAMBRIDGE MA 02140

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9.13	03/04/2026		A		150,000		(1)	03/03/2036	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. The option vests and become exercisable in 36 equal monthly installments.

Remarks:

Interim Chief Executive Officer

	/s/ Thomas J. DesRosier, Attorney-in-Fact for Richard N. Kender	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity award did Richard N. Kender receive at Seres Therapeutics (MCRB)?

Richard N. Kender received a grant of stock options for 150,000 shares of Seres Therapeutics common stock. The options were reported as a direct holding and represent equity-based compensation for his role as a director and officer.

How do Richard N. Kender’s new stock options at MCRB vest?

The stock options granted to Richard N. Kender vest in 36 equal monthly installments. This structure spreads vesting over three years, encouraging ongoing service and alignment with Seres Therapeutics’ long-term performance and governance goals.

Is Richard N. Kender’s Form 4 transaction at Seres Therapeutics a buy or a sale?

The Form 4 shows an acquisition of stock options by grant, not an open-market buy or sale. It records compensation in the form of 150,000 option rights rather than a purchase or disposition of existing Seres Therapeutics shares.

How many Seres Therapeutics (MCRB) options does Richard N. Kender hold after this grant?

After the reported grant, Richard N. Kender holds 150,000 stock options according to the filing. This reflects the total derivative securities following the transaction, all subject to the vesting schedule described for the option award.

What does the Form 4 filing imply about Richard N. Kender’s ownership type in MCRB options?

The filing classifies the option grant as direct ownership by Richard N. Kender. This means the options are held in his name rather than through an intermediary entity such as a trust, partnership, or family investment vehicle.